30 closest matches · ranked by relevance
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Breast Cancer
Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort
Metastatic Triple Negative Breast Cancer
Primary: Asses the Maximum Tolerated Dose (MTD) of L-NMMA When Combined With Docetaxel/Amlodipine in the Treatment of Refractory Locally Advanced or Metastatic TNBC Patients…
Advanced and / or Metastatic Liposarcoma
Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants
Locally Advanced Pancreatic Adenocarcinoma
Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
Non-small Cell Lung Cancer
Primary: Local Failure Free Survival — 9.4; 9.9 months
Breast Cancer · Breast Neoplasms
Primary: Number of Participants Who Were Successfully Accrued in the Study, as a Measure of Feasibility — 35 participants
Advanced Solid Tumors
Primary: Overall Response Rate (ORR) — 5.6; 0.0; 11.3; 14.3 percentage of participants
Neoplasms · Pancreatic Neoplasms
Primary: Objective Response (OR) (Partial Responses + Complete Responses) in Phase 2 Subjects of Short Infusion LMB-100+ Nab-paclitaxel — 1 Participants
Pancreatic Neoplasms
Primary: Kaplan-Meier Estimates for Time to Treatment Failure (TTF) — 9.0 months
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Major Pathologic Response (MPR) — 20.3 percentage of participants — p=<.0001
Metastatic Leiomyosarcoma
Primary: Response Rate (Per RECIST 1.1) — 1 Participants
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) · Pancreatic Ductal Adenocarcinoma
Primary: Study Drug-related Adverse Events — 3; 6; 3; 5 Participants
Advanced Nonhematological Malignancies · Non-Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 2 participants
Carcinoma, Non Small Cell Lung (NSCLC)
Primary: The Metabolic Complete Response Rate, Assessed Using Interim PET-CT, in an Accelerated Fashion (2 Gy/Fraction, 6 Fractions/Week) With Concurrent Chemotherapy — 1; 6; 1…
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Basal Cell Carcinoma
Primary: Progression Free Survival (PFS) of All Participants — 6; 36 weeks
Melanoma
Primary: Th1/Th2 Normalized Gene Expression — 1.029; 0.119; 0.074; 0.192 fold change
Neuroendocrine Carcinoma of the Lung and Thymus
Primary: Percentage of Participants Progression-free at 9 Months Based on Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) — 0; 0; 0; 2.4 percentage of participants
Sarcoma
Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants
Solid Tumors
Primary: Dose-escalation Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0 Participants
Solid Tumor, Adult
Primary: Number of Participants With Adverse Events (AEs), and Serious Adverse Events (SAEs). — 11; 3 Participants
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Advanced Cancer
Primary: Urinary and Fecal Excretion of LY2603618 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 72.2; 11.0 percentage of total dose
Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
Primary: Overall Response Rate (ORR) — 0; 3; 19; 2 Participants
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 percentage of participants
Stage T3-4NxM0 Gastric Cancer
Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants
Pancreatic Cancer
Primary: The Maximum Tolerated Dose (MTD) of Stereotactic Body Radiotherapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients Who Have Not Developed Distant…